로딩 중…
지수 로딩 중…
Seegene, Inc.
096530· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩27,800-3.47%
2026-06-19
Price Chart
Seegene, Inc.-17.75%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 1.45T KRW |
| Revenue | 487.37B KRW |
| Net Income | 54.12B KRW |
| Total Assets | 1.26T KRW |
| Net Assets | 1.02T KRW |
| Employees | 862 |
| Value | |
| P/E | 26.83x |
| P/B | 1.42x |
| PEG | 1.33x |
| P/S | 2.98x |
| EV/EBITDA | 81.20x |
| FCF Yield | 7.71% |
| Profitability | |
| ROE | 5.29% |
| ROA | 4.31% |
| Op. Margin | 8.88% |
| Revenue Growth | 11.33% |
| Earnings Growth | 20.24% |
| Financial Health | |
| Debt Ratio | 122.71% |
| Total Debt | 77.09B KRW |
| FCF | 111.98B KRW |
| Cash | 257.96B KRW |
| Current Ratio | 4.46x |
| Net Debt/EBITDA | -11.55x |
| Dividend | |
| Div. Yield | 3.47% |
| Div. Growth | 25.00% |
| Performance | |
| 1Y Return | -17.75% |
| 1M Return | -7.02% |
| From 52W High | -22.13% |
| 1Y MDD | -37.84% |
| Trading | |
| Volume | 186,816 shares |
| Foreign Own. | 17.78% |
| Per Share | |
| EPS | 1,257 KRW |
| BPS | 22,455 KRW |
Company Info
Seegene, established in 2000 and headquartered in Songpa-gu, Seoul, focuses on developing gene analysis technology and reagents. The company engages in the development, manufacturing, and sales of molecular diagnostic reagents that identify disease causes through gene analysis, possessing high-multiplex syndromic quantitative PCR technology. With agencies in over 100 countries including Italy, UAE, USA, and Canada, Seegene is actively expanding its global sales network and acquired 100% of Dandi Meka's shares in 2025.